Floatz logo

gi-6301

Malignant Solid Tumors

National Cancer Institute (NCI)vaccinePhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

30 Active assets in the Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Peg-Rhg-Csf
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4B
Medroxyprogesterone acetate
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
DEXAMETHASONE
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Zofran
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B

View all 38 →

Same molecule, other indications

gi-6301 is also rated in:

triple-negative breast carcinomaDormant
C
Indicative ·
38 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
38 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →